Celldex posts preclinical data from CDX-585 PD-1/ILT4 bispecific antibody program

seekingalpha2021-11-12

Celldex Therapeutics(NASDAQ:CLDX)announces preclinical data from CDX-585, the company’s bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways, developed from its bispecific ...

网页链接
免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

发表看法
6